Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,106,960
  • Shares Outstanding, K 76,924
  • Annual Sales, $ 937,820 K
  • Annual Income, $ -626,600 K
  • EBIT $ -8 M
  • EBITDA $ 446 M
  • 60-Month Beta 0.63
  • Price/Sales 3.32
  • Price/Cash Flow 16.70
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 67.65% ( +3.20%)
  • Historical Volatility 61.97%
  • IV Percentile 33%
  • IV Rank 15.03%
  • IV High 165.94% on 01/24/24
  • IV Low 50.26% on 10/25/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 158
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 3,940
  • Open Int (30-Day) 3,443

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.54
  • Number of Estimates 8
  • High Estimate -0.91
  • Low Estimate -2.09
  • Prior Year -1.76
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.57 +16.66%
on 10/07/24
43.40 -7.07%
on 10/24/24
+5.23 (+14.90%)
since 10/04/24
3-Month
29.01 +39.00%
on 08/09/24
43.40 -7.07%
on 10/24/24
+9.33 (+30.10%)
since 08/05/24
52-Week
18.15 +122.20%
on 11/13/23
43.40 -7.07%
on 10/24/24
+20.80 (+106.50%)
since 11/03/23

Most Recent Stories

More News
3 Top Stocks That Could Still Rocket Higher in 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

PTCT : 40.80 (+1.02%)
VRTX : 490.67 (+3.78%)
BBIO : 24.94 (-1.03%)
RHHBY : 38.7800 (-1.65%)
PFE : 27.79 (+0.11%)
PTC Therapeutics: Q2 Earnings Snapshot

PTC Therapeutics: Q2 Earnings Snapshot

PTCT : 40.80 (+1.02%)
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

Stocks that traded heavily or had substantial price changes on Friday: Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise

FCX : 46.76 (+1.06%)
PTCT : 40.80 (+1.02%)
ACCD : 3.20 (+1.59%)
KRUS : 98.62 (+6.15%)
PTGX : 45.63 (-2.42%)
INFN : 6.73 (+0.15%)
PTC Therapeutics: Q1 Earnings Snapshot

PTC Therapeutics: Q1 Earnings Snapshot

PTCT : 40.80 (+1.02%)
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 40.80 (+1.02%)
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

SRPT : 123.09 (+0.02%)
PTCT : 40.80 (+1.02%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 40.80 (+1.02%)
Why PTC Therapeutics Soared 15% Higher Today

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTCT : 40.80 (+1.02%)
RPRX : 27.25 (+0.18%)
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023...

PTCT : 40.80 (+1.02%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

PTCT : 40.80 (+1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 43.25
2nd Resistance Point 42.28
1st Resistance Point 41.34
Last Price 40.80
1st Support Level 39.43
2nd Support Level 38.46
3rd Support Level 37.52

See More

52-Week High 43.40
Last Price 40.80
Fibonacci 61.8% 33.75
Fibonacci 50% 30.78
Fibonacci 38.2% 27.80
52-Week Low 18.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar